17ß-oestradiol acts as a negative modulator of insulin-induced lactotroph cell proliferation through oestrogen receptor α, via nitric oxide/guanylyl cyclase/cGMP.

OBJECTIVES: 17ß-oestradiol interacts with growth factors to modulate lactotroph cell population. However, contribution of isoforms of the oestrogen receptor in these activities is not fully understood. In the present study, we have established participation of α and ß oestrogen receptors in effects of 17ß-oestradiol on lactotroph proliferation induced by insulin and shown involvement of the NO/sGC/cGMP pathway. MATERIALS AND METHODS: Cell cultures were prepared from anterior pituitaries of female rats to evaluate lactotroph cell proliferation using bromodeoxyuridine (BrdUrd) detection, protein expression by western blotting and cGMP by enzyme immunoassay. RESULTS: In serum-free conditions, 17ß-oestradiol and α and ß oestrogen receptor agonists (PPT and DPN) failed to increase numbers of lactotroph cells undergoing mitosis. Co-incubation of 17ß-oestradiol/insulin and PPT/insulin significantly decreased lactotroph mitogenic activity promoted by insulin alone. Both ICI 182780 and NOS inhibitors (L-NMMA and L-NAME) induced reversal of the anti-proliferative effect promoted by 17ß-oestradiol/insulin and PPT/insulin. Moreover, 17ß-oestradiol, PPT and insulin increased sGC α1 protein expression and inhibited ß1, whereas co-incubation of 17ß-oestradiol/insulin or PPT/insulin induced increases of the two isoforms α1 and ß1. 17ß-oestradiol and insulin reduced cGMP production, while 17ß-oestradiol/insulin co-incubation increased this cyclic nucleotide. CONCLUSIONS: Our results suggest that 17ß-oestradiol is capable of arresting lactotroph proliferation induced by insulin through ER α with participation of the signalling NO/sGC/cGMP pathway.

Behaviour of a somatotroph population under a growth hormone releasing peptide treatment.

In this investigation, we studied the effects of Momany peptide (GHRP-5), on somatotroph secretory activity. Acute and chronic administration of GHRP-5 provokes a significant release of growth hormone that can be closely correlated with ultrastructural changes in somatotroph populations. After 3,5 and 7 days of GHRP-5 treatment, two somatotroph cell subpopulations coexist. One of them has an enhanced secretory activity and the other presents a quiescent appearance. Therefore, pituitary growth hormone content was not affected in the first seven days of GHRP-5 treatment. After 14 days, there was a significant depletion of growth hormone pituitary content coincident with the highest levels of serum growth hormone. These results concur with the surge of a new hyperactive somatotroph subtype characterised by numerous immature secretory granules that are discharged bypassing the maturation step. Acute and chronic treatments caused no changes in somatotroph cell density, the area immunostained for growth hormone and the levels of total mRNA for transcription factor pit-1. The results of pituitary cell cultures incubated with specific blockers for different signalling pathways demonstrated an involvement of the phospholipase C-inositol phosphate system in GHRP-5 stimulated somatotroph secretion. GHRP-5 treatment enhanced significantly the release of growth hormone, thereby eliciting ultrastructural modifications in somatotrophs that can be correlated with an increased secretory activity devoid of cell density changes.

Somatotroph response to periodical IGF-I administration to male rats.

Insulin-like growth factor I (IGF-I) downregulates growth hormone (GH) expression in pituitary cell cultures. However, in vivo different results were found depending on the experimental protocol used. We determined the kinetics of changes of pituitary and serum GH concentrations after subcutaneous IGF-I administration (240 microg/100 g body weight) to rats every 12 h for various periods. These parameters were correlated with changes in the somatotroph cell population. A significant increase in serum GH was registered at 6 h after IGF-I injection. At this time, some somatotroph cells exhibited ultrastructurally signs of high secretory activity, whereas adjacent somatotroph cells showed a quiescent appearance with sizeable stores of secretory granules. In contrast, serum GH levels remained unchanged at 1, 2 and 12 h after each IGF-I injection. Pituitary GH concentrations were comparable to control levels during the first 48 h and declined significantly at 72 h and 96 h of IGF-I treatment. After these prolonged periods of time of treatment, the size and extension of organelles involved in protein synthesis decreased and mature secretory granules in the cytoplasm increased significantly in GH-secreting cells. The somatotroph cell density remained unchanged even at 96 h of treatment. In conclusion, our results suggest that periodical IGF-I administration to rats does not inhibit GH secretion. Interestingly, IGF-I injections induced early and significant increases in serum GH levels. This result may be a consequence of a temporary stimulatory action on somatotroph cells concurrent with increased secretory activity.

Cellular and functional interactions between gonadotrophs and lactotrophs in pituitary cell cultures.

Lactotroph secretory activity is regulated by hypothalamic stimulating and inhibiting factors as well as peripheral endocrine hormones. In addition to this important control domain, the pituitary gland displays an intrinsic regulatory ability through autocrine and paracrine signals. To evaluate the role of gonadotrophs in the regulation of prolactin (PRL) secretion, a comparative study was performed applying two regulatory agents that operate through different physiological mechanisms: gonadotropin-releasing hormone (GnRH), which releases regulatory factors co-localized in secretory granules of gonadotrophs, stimulating PRL secretion from lactotrophs; and angiotensin II (AII), with direct effects on lactotroph secretion through specific receptors. In these studies performed in regular and purified primary pituitary cell cultures from female rats, the lactotrophs comprised the largest population of cells (about 51%), whereas gonadotrophs represented only a small fraction (3%) of the total pituitary cell count. In regular cell cultures treatments with AII and GnRH showed a similar secretory behavior, increasing PRL output 73% and 63%, respectively. The stimulation with GnRH and AII of cell cultures with purified lactotrophs and gonadotrophs provided comparable results, but the response of lactotrophs was significantly higher (106% and 138%, respectively) than that recorded in regular cell cultures. Simultaneous AII treatment with an antipeptide antagonist to AII receptor (AII-antipep) completely blocked the PRL release induced by AII. The co-incubation of cells with GnRH and AII-antipep suppressed the peak of PRL release caused by GnRH, confirming that AII is a paracrine agent released by gonadotrophs stimulated with GnRH. The different secretory behavior of lactotrophs treated with AII and GnRH in both regular and purified cell cultures is indicative of the degree of functional interactions between different pituitary cell types. The present study supplies morphological and functional information on the cell-to-cell interactions, which plays an important role in the intrinsic regulatory control of PRL secretion.

Heterogeneity of pituitary lactotrophs: immunocytochemical identification of functional subtypes.

The existence of functional lactotroph subpopulations was confirmed in primary pituitary cell cultures of female rats submitted to estrogen treatment and stimulation with thyrotrophin releasing hormone (TRH) and angiotensin II (A-II). In cell cultures of pituitary tissue, prolactin (PRL) producing cells represent about 50% of the total cell count, most of which (90%) correspond to a typical lactotroph subpopulation characterized by large secretory granules, 500-900 nm in diameter, and well developed rough endoplasmic reticulum (RER) and Golgi complex. Few atypical lactotrophs were detected with a quiescent appearance and containing smaller secretory granules, often indistinguishable from granular content of other pituitary cells. Depletion of endogenous estrogen caused by ovariectomy (OVX) decreased the pituitary lactotroph population about 34%, with a relative increase of atypical forms (56%). Replacement therapy with benzoate estradiol (EB) to OVX rats did not reverse the proportion of typical and atypical lactotrophs gauged in control pituitary glands. The predominant lactotroph population of OVX rat was an atypical PRL producing cell which displayed a quiescent appearance compatible with a reduced secretory activity. By contrast, estrogen administration to OVX rats caused a striking development of the RER, a hypertrophy of the Golgi complex and an increased storage of mature and immature secretory granules in the majority of lactotrophs. These features are compatible with a reactivated protein synthesis. Estrogen also enhanced significantly (p < 0.05) the responsiveness of lactotrophs to A-II and the PRL secretion in both intact and OVX + EB treated rats increased by 40% and 30% respectively. By contrast, A-II did not produce any statistically significant response of lactotrophs from OVX female rats. At variance to this observation, in all models tested TRH increased significantly the PRL secretion (p < 0.05). The correlation of PRL secretion and morphology of different lactotroph subtypes authenticates the existence of a lactotroph subpopulation unresponsive to A-II in pituitary cell cultures from rats depleted of estrogen.